Hozair Syed, MD
Psychiatry · Pismo Beach, CANPI 1235342098
Payments from drug & device makers
Across 802 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Alkermes, Inc.$2K
- Johnson & Johnson$1K
- AbbVie$1K
- Neurocrine Biosciences, Inc.$934
- plus $4K from 21 others
What the payments were for
- Food & beverage$13,17097%
- Education$3393%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 129 | $2,327 |
| Otsuka America Pharmaceutical, Inc. | 131 | $1,930 |
| Alkermes, Inc. | 62 | $1,505 |
| Johnson & Johnson | 79 | $1,366 |
| AbbVie(2 entities) | 67 | $1,100 |
| Neurocrine Biosciences, Inc. | 38 | $934 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 41 | $690 |
| Indivior Inc. | 32 | $688 |
| Lundbeck LLC | 56 | $636 |
| E.r. Squibb & Sons, L.L.C. | 29 | $569 |
| Sunovion Pharmaceuticals Inc. | 69 | $479 |
| Axsome Therapeutics, Inc. | 17 | $345 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $227 |
| Supernus Pharmaceuticals, Inc. | 9 | $201 |
| Almatica Pharma LLC | 5 | $87 |
| Vanda Pharmaceuticals Inc. | 4 | $79 |
| Avanir Pharmaceuticals, Inc. | 3 | $69 |
| Tris Pharma Inc | 4 | $60 |
| Arbor Pharmaceuticals, Inc. | 3 | $56 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Bausch Health US, LLC | 1 | $24 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Corium, LLC | 1 | $18 |
| Luye Pharma (USA) Ltd. | 1 | $18 |
| Merck | 1 | $17 |
| Tonix Medicines, Inc. | 1 | $17 |
| Noven Therapeutics, LLC | 1 | $14 |
How this compares
$13,509 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 33 | $173,851 |
| Austedo XrDeutetrabenazine | 16 | $153,829 |
| Invega SustennaPaliperidone Palmitate | 32 | $88,182 |
| VraylarCariprazine Hcl | 59 | $78,249 |
| PerserisRisperidone | 32 | $75,107 |
| RexultiBrexpiprazole | 49 | $68,483 |
| LybalviOlanzapine/Samidorphan Malate | 29 | $42,523 |
| TrintellixVortioxetine Hydrobromide | 73 | $36,582 |
| NuedextaDextromethorphan Hbr/Quinidine | 16 | $12,065 |
| Trazodone Hcl | 332 | $4,368 |
| Lurasidone Hcl | 131 | $3,039 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 80 | $2,570 |
| Aripiprazole | 148 | $2,157 |
| Benztropine Mesylate | 250 | $2,124 |
| Buspirone Hcl | 255 | $2,070 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $2,327 | $327,68049 claims |
| Johnson & JohnsonInvega Sustenna | $1,366 | $88,18232 claims |
| AbbVieVraylar | $1,100 | $78,24959 claims |
| Indivior Inc.Perseris | $688 | $75,10732 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,930 | $68,48349 claims |
| Alkermes, Inc.Lybalvi | $1,505 | $42,52329 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $227 | $36,58273 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $69 | $12,06516 claims |
| Almatica Pharma LLCSertraline Hcl | $87 | $855155 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Pismo Beach
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.